Cytogenetics and molecular biological markers in oncology and hematooncology;Cytogenetické a molekulárně biologické markery v onkologii solidních nádorů a hematologických malignit

Klinicka Onkologie

Volumn 17, Issue SUPPL., 2004, Pages 51-56

  Hajduch M ^a   Jarosova M ^a   Trojanec, R ^a   Indrak K ^a   Spackova K ^a   Papajik T ^a   Cwiertka, K ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Acute promyelocytic leukemia; All trans retinoid acid; bcr abl; Breast cancer; Chronic myeloid leukemia; ERBB2; Imatinib mesylate; PML RAR ; Trastuzumab

Indexed keywords

EID: 33744821445     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ. A szstematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma an neuroblastoma. Health and Technology Assessment 2003; 7, 1-159.
2. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health and Technology Assessment 1998; 2, 1-83.
3. Mihál V, Hajdúch M, Janošt'áková A, Šafářová M, Nosková V, Pospíš ilová D, Novák Z: Využití in vitro analýzy lékové rezistence v léčbě leukémií dětského věku. Klin Onkol 2000; 13: 39-42.
4. Talač R, Žaloudík J, Hajdúch M, Mihál V, Chumchalová J, Hanke I, Kovařík J: Hodnocení lékové rezistence in vitro a její klinické implikace. Klin Onkol 2000; 13: 2-3.
5. Hynes NE, Stern DF: The biology of erb-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1994; 1198: 165-84.
6. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
7. Klapper LN, Kirschbaum MH ,Selas M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. In Klein G, Woude V (eds): Advaces in Cancer Research. New York: Academic Press 2000; 25-79.
8. Barnes DM, Bartkova J, Camplejohn RS, et al.: Overexpression of the cerbB-2 oncogene: why does it occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significans? Eur J Cancer l992; 28: 644-8.
9. Bast RC, Radvin P, Hayes DF, et al.: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
10. Jacobs TW, Gown AM, Yaziji H, Barnes MJ: Specifity of Herceptest in determining Her-2/neu status of breast cancers using the United States Food and Drug Administration-aproved scoring System. J Clin Oncol 1999; 17 (7): 1983.
11. Press MF, Bernstein L, Thomas PA: Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15 (8): 2894-2904.
12. Jacobs TW, Gown AM, Yaziji H, Barnes MJ: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of Her-2/neu in breast cancer. J Clin Oncol 1999; 17 (7): 1974-65.
13. Ellis IO, Dowsett M, Barlett J, et al.: Recommendations for HER2 testing in UK. J Clin Path 2000; 53(12): 890-892.
14. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature,1973;243:290-293.
15. Grimwade, D., Walker,H., Oliver,F., at al.: The importance of diagnostic Cytogenetics on outcome in AML: Analysis of 1,612 patients into the MRC AML 10 trial.Blood,92,7,1998,2322-2333.
16. Berger,R., Bernheim,A., Ochoa-Noguera,M.E., et al.: Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia.A study of 343 patients. Cancer Genet Cytogenet 28, 1987, 293-297.
17. Druker BJ, Sawyers CL, Kantarjian H , et al: Activity of a specific inhibitor of the BCR-ABL tyrosin kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344: 1038-1042.
18. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N.Engl J Med. 2002;346:645-652.
19. Sawyers CL, Hochhaus A,Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood,2002;99:3530-3539.
20. Harris,L.N., Jaffe,E.S., Diebold,J., et al.: The World Health Organization Classification of Neoplastic Diseases of Hematopoietic and Lymphoid Tissues. Ann.Oncol.,10,1999,s.1419-1432.
21. Grimwade,D., Gorman,P., Duprez,E., et al.: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.Blood,90,1997,4876-4885.
22. Warrell RJ, Richon V, et al: Thearapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetelase. J Natl Cancer Inst. 1998;90: 1621-1625.